{"status": "Succeeded", "recognitionResults": [{"page": 1, "clockwiseOrientation": 0.07, "width": 1700, "height": 2236, "unit": "pixel", "lines": [{"boundingBox": [288, 136, 651, 140, 650, 188, 287, 183], "text": "Top-Line Summary", "words": [{"boundingBox": [291, 136, 460, 139, 460, 186, 291, 183], "text": "Top-Line"}, {"boundingBox": [469, 139, 650, 141, 649, 186, 469, 186], "text": "Summary"}]}, {"boundingBox": [330, 206, 1299, 203, 1300, 240, 331, 242], "text": "Eight Regional Market Research Consultants Meetings were held in", "words": [{"boundingBox": [335, 206, 412, 207, 410, 242, 333, 242], "text": "Eight"}, {"boundingBox": [419, 207, 545, 208, 544, 242, 417, 242], "text": "Regional"}, {"boundingBox": [552, 208, 652, 209, 651, 242, 551, 242], "text": "Market"}, {"boundingBox": [659, 209, 794, 209, 793, 241, 658, 242], "text": "Research"}, {"boundingBox": [801, 209, 978, 209, 978, 240, 800, 241], "text": "Consultants"}, {"boundingBox": [985, 209, 1118, 208, 1118, 239, 985, 240], "text": "Meetings"}, {"boundingBox": [1125, 208, 1195, 207, 1195, 239, 1125, 239], "text": "were"}, {"boundingBox": [1202, 207, 1267, 206, 1268, 238, 1202, 238], "text": "held"}, {"boundingBox": [1274, 206, 1300, 206, 1300, 237, 1275, 238], "text": "in"}]}, {"boundingBox": [329, 244, 1233, 242, 1234, 276, 330, 278], "text": "October and November 2001. Each location featured the same", "words": [{"boundingBox": [334, 245, 450, 245, 451, 277, 336, 276], "text": "October"}, {"boundingBox": [456, 245, 510, 244, 511, 278, 458, 277], "text": "and"}, {"boundingBox": [516, 244, 667, 244, 668, 278, 517, 278], "text": "November"}, {"boundingBox": [673, 244, 759, 244, 761, 278, 674, 278], "text": "2001."}, {"boundingBox": [766, 244, 838, 244, 840, 278, 767, 278], "text": "Each"}, {"boundingBox": [844, 244, 964, 244, 966, 277, 846, 278], "text": "location"}, {"boundingBox": [972, 244, 1094, 245, 1096, 275, 974, 277], "text": "featured"}, {"boundingBox": [1100, 245, 1148, 245, 1150, 274, 1102, 275], "text": "the"}, {"boundingBox": [1154, 245, 1232, 245, 1234, 273, 1156, 274], "text": "same"}]}, {"boundingBox": [337, 282, 1287, 278, 1288, 313, 338, 317], "text": "program: 1) A 3-hour plenary session featuring speakers and Q&A;", "words": [{"boundingBox": [339, 283, 470, 282, 469, 317, 338, 318], "text": "program:"}, {"boundingBox": [476, 282, 504, 282, 503, 317, 476, 317], "text": "1)"}, {"boundingBox": [511, 282, 531, 282, 531, 317, 510, 317], "text": "A"}, {"boundingBox": [538, 282, 630, 282, 629, 317, 538, 317], "text": "3-hour"}, {"boundingBox": [637, 282, 747, 282, 747, 316, 636, 317], "text": "plenary"}, {"boundingBox": [754, 282, 866, 281, 866, 316, 754, 316], "text": "session"}, {"boundingBox": [873, 281, 1006, 281, 1006, 315, 873, 316], "text": "featuring"}, {"boundingBox": [1013, 281, 1146, 280, 1146, 314, 1013, 315], "text": "speakers"}, {"boundingBox": [1153, 280, 1208, 280, 1208, 314, 1153, 314], "text": "and"}, {"boundingBox": [1215, 280, 1286, 280, 1286, 313, 1215, 314], "text": "Q&A;"}]}, {"boundingBox": [334, 317, 1220, 315, 1221, 350, 335, 352], "text": "and 2) 90-minute breakout discussion sessions in which High", "words": [{"boundingBox": [336, 317, 390, 317, 390, 352, 335, 352], "text": "and"}, {"boundingBox": [397, 317, 422, 317, 422, 352, 397, 352], "text": "2)"}, {"boundingBox": [429, 317, 571, 317, 571, 352, 429, 352], "text": "90-minute"}, {"boundingBox": [578, 317, 716, 317, 715, 352, 578, 352], "text": "breakout"}, {"boundingBox": [722, 317, 876, 317, 875, 351, 722, 352], "text": "discussion"}, {"boundingBox": [883, 317, 1013, 317, 1013, 351, 882, 351], "text": "sessions"}, {"boundingBox": [1020, 317, 1047, 317, 1047, 350, 1020, 351], "text": "in"}, {"boundingBox": [1054, 317, 1144, 317, 1143, 350, 1054, 350], "text": "which"}, {"boundingBox": [1150, 317, 1219, 317, 1219, 350, 1150, 350], "text": "High"}]}, {"boundingBox": [332, 353, 1118, 354, 1118, 389, 331, 388], "text": "Potential TZD users were separated from TZD Splitters.", "words": [{"boundingBox": [334, 354, 464, 354, 464, 389, 334, 387], "text": "Potential"}, {"boundingBox": [471, 354, 528, 354, 528, 389, 471, 389], "text": "TZD"}, {"boundingBox": [535, 354, 616, 355, 616, 389, 535, 389], "text": "users"}, {"boundingBox": [623, 355, 696, 355, 696, 389, 623, 389], "text": "were"}, {"boundingBox": [702, 355, 845, 354, 845, 389, 702, 389], "text": "separated"}, {"boundingBox": [852, 354, 914, 354, 914, 389, 852, 389], "text": "from"}, {"boundingBox": [931, 354, 986, 354, 986, 389, 931, 389], "text": "TZD"}, {"boundingBox": [997, 354, 1119, 354, 1119, 387, 997, 388], "text": "Splitters."}]}, {"boundingBox": [331, 406, 1320, 404, 1321, 439, 332, 440], "text": "These meetings included 350 targeted primary care physicians- 181", "words": [{"boundingBox": [336, 407, 421, 407, 421, 440, 336, 440], "text": "These"}, {"boundingBox": [427, 407, 561, 408, 562, 441, 427, 440], "text": "meetings"}, {"boundingBox": [568, 408, 695, 408, 696, 441, 568, 441], "text": "included"}, {"boundingBox": [702, 408, 752, 408, 752, 441, 702, 441], "text": "350"}, {"boundingBox": [758, 408, 879, 408, 880, 441, 759, 441], "text": "targeted"}, {"boundingBox": [886, 408, 998, 407, 999, 440, 887, 441], "text": "primary"}, {"boundingBox": [1005, 407, 1067, 407, 1069, 440, 1006, 440], "text": "care"}, {"boundingBox": [1074, 407, 1251, 405, 1253, 439, 1075, 440], "text": "physicians-"}, {"boundingBox": [1271, 405, 1318, 405, 1320, 438, 1272, 439], "text": "181"}]}, {"boundingBox": [331, 441, 1163, 443, 1162, 478, 330, 476], "text": "High Potentials and 169 TZD Splitters. The presentations", "words": [{"boundingBox": [334, 442, 401, 442, 401, 478, 333, 478], "text": "High"}, {"boundingBox": [408, 442, 553, 443, 553, 477, 408, 478], "text": "Potentials"}, {"boundingBox": [560, 443, 616, 443, 616, 477, 560, 477], "text": "and"}, {"boundingBox": [623, 443, 677, 443, 676, 477, 623, 477], "text": "169"}, {"boundingBox": [684, 443, 740, 443, 740, 477, 683, 477], "text": "TZD"}, {"boundingBox": [747, 443, 890, 444, 889, 477, 747, 477], "text": "Splitters."}, {"boundingBox": [897, 444, 948, 444, 948, 477, 896, 477], "text": "The"}, {"boundingBox": [955, 444, 1161, 445, 1160, 477, 955, 477], "text": "presentations"}]}, {"boundingBox": [337, 480, 1068, 479, 1068, 514, 338, 515], "text": "strengthened already-positive perceptions of TZDs.", "words": [{"boundingBox": [339, 481, 525, 480, 524, 515, 338, 514], "text": "strengthened"}, {"boundingBox": [532, 480, 759, 480, 759, 516, 531, 515], "text": "already-positive"}, {"boundingBox": [766, 480, 943, 480, 942, 515, 765, 516], "text": "perceptions"}, {"boundingBox": [949, 480, 980, 480, 980, 515, 949, 515], "text": "of"}, {"boundingBox": [987, 480, 1067, 480, 1066, 515, 986, 515], "text": "TZDs."}]}, {"boundingBox": [331, 541, 1358, 538, 1359, 572, 332, 574], "text": "Participants in all groups agree that insulin resistance is the primary or", "words": [{"boundingBox": [334, 541, 505, 542, 505, 574, 334, 574], "text": "Participants"}, {"boundingBox": [512, 542, 542, 542, 542, 574, 512, 574], "text": "in"}, {"boundingBox": [548, 542, 585, 543, 585, 574, 549, 574], "text": "all"}, {"boundingBox": [591, 543, 695, 543, 696, 574, 592, 574], "text": "groups"}, {"boundingBox": [702, 543, 782, 543, 782, 574, 702, 574], "text": "agree"}, {"boundingBox": [788, 543, 846, 543, 847, 574, 789, 574], "text": "that"}, {"boundingBox": [853, 543, 952, 543, 953, 574, 854, 574], "text": "insulin"}, {"boundingBox": [959, 542, 1110, 542, 1111, 573, 960, 574], "text": "resistance"}, {"boundingBox": [1117, 541, 1147, 541, 1148, 573, 1118, 573], "text": "is"}, {"boundingBox": [1153, 541, 1199, 541, 1200, 573, 1155, 573], "text": "the"}, {"boundingBox": [1205, 541, 1317, 539, 1319, 572, 1206, 573], "text": "primary"}, {"boundingBox": [1324, 539, 1356, 539, 1358, 571, 1325, 572], "text": "or"}]}, {"boundingBox": [332, 574, 894, 577, 893, 609, 331, 606], "text": "foundational defect in Type 2 diabetes.", "words": [{"boundingBox": [334, 575, 522, 578, 523, 608, 335, 606], "text": "foundational"}, {"boundingBox": [528, 578, 613, 578, 613, 609, 529, 608], "text": "defect"}, {"boundingBox": [619, 578, 646, 578, 647, 609, 619, 609], "text": "in"}, {"boundingBox": [656, 578, 725, 578, 726, 609, 657, 609], "text": "Type"}, {"boundingBox": [731, 578, 753, 578, 753, 609, 732, 609], "text": "2"}, {"boundingBox": [761, 578, 893, 577, 894, 610, 761, 609], "text": "diabetes."}]}, {"boundingBox": [324, 626, 1211, 627, 1210, 663, 323, 662], "text": "Most believe intuitively that TZDs preserve beta cell function.", "words": [{"boundingBox": [334, 628, 407, 628, 406, 661, 333, 660], "text": "Most"}, {"boundingBox": [413, 628, 514, 629, 513, 662, 412, 661], "text": "believe"}, {"boundingBox": [521, 630, 665, 630, 664, 663, 520, 662], "text": "intuitively", "confidence": "Low"}, {"boundingBox": [671, 630, 731, 630, 731, 663, 670, 663], "text": "that"}, {"boundingBox": [738, 630, 811, 630, 810, 663, 737, 663], "text": "TZDs", "confidence": "Low"}, {"boundingBox": [817, 630, 946, 630, 946, 663, 817, 663], "text": "preserve"}, {"boundingBox": [953, 630, 1017, 629, 1017, 663, 952, 663], "text": "beta"}, {"boundingBox": [1024, 629, 1077, 629, 1077, 663, 1023, 663], "text": "cell"}, {"boundingBox": [1084, 629, 1210, 627, 1210, 661, 1083, 663], "text": "function."}]}, {"boundingBox": [333, 679, 1330, 680, 1329, 717, 332, 716], "text": "If convinced by clinical data that TZDs do, in fact, preserve beta cells,", "words": [{"boundingBox": [334, 680, 355, 680, 353, 716, 333, 716], "text": "If"}, {"boundingBox": [362, 680, 508, 681, 507, 717, 360, 716], "text": "convinced"}, {"boundingBox": [515, 681, 552, 681, 551, 717, 514, 717], "text": "by"}, {"boundingBox": [559, 681, 670, 681, 669, 717, 558, 717], "text": "clinical"}, {"boundingBox": [677, 681, 733, 681, 732, 718, 676, 717], "text": "data"}, {"boundingBox": [740, 681, 800, 681, 799, 718, 739, 718], "text": "that"}, {"boundingBox": [807, 681, 881, 681, 880, 718, 806, 718], "text": "TZDs"}, {"boundingBox": [888, 681, 934, 681, 934, 718, 887, 718], "text": "do,"}, {"boundingBox": [941, 681, 971, 681, 971, 717, 941, 718], "text": "in"}, {"boundingBox": [978, 681, 1041, 681, 1040, 717, 978, 717], "text": "fact,"}, {"boundingBox": [1048, 681, 1175, 681, 1175, 717, 1047, 717], "text": "preserve"}, {"boundingBox": [1182, 681, 1245, 681, 1245, 716, 1182, 717], "text": "beta"}, {"boundingBox": [1252, 681, 1328, 681, 1328, 715, 1252, 716], "text": "cells,"}]}, {"boundingBox": [335, 718, 1359, 717, 1360, 751, 336, 753], "text": "many participants would feel compelled to use TZDs as 1\"-line therapy.", "words": [{"boundingBox": [336, 722, 413, 721, 412, 752, 336, 752], "text": "many"}, {"boundingBox": [418, 721, 591, 720, 591, 752, 418, 752], "text": "participants"}, {"boundingBox": [596, 719, 688, 719, 689, 752, 597, 752], "text": "would"}, {"boundingBox": [694, 719, 747, 719, 747, 752, 694, 752], "text": "feel"}, {"boundingBox": [753, 719, 905, 718, 906, 753, 753, 752], "text": "compelled"}, {"boundingBox": [911, 718, 943, 718, 943, 753, 912, 753], "text": "to"}, {"boundingBox": [948, 718, 1003, 718, 1004, 752, 949, 753], "text": "use"}, {"boundingBox": [1013, 718, 1089, 718, 1090, 752, 1014, 752], "text": "TZDs"}, {"boundingBox": [1095, 718, 1130, 718, 1131, 752, 1096, 752], "text": "as"}, {"boundingBox": [1138, 718, 1234, 718, 1235, 752, 1139, 752], "text": "1\"-line", "confidence": "Low"}, {"boundingBox": [1240, 718, 1357, 718, 1358, 752, 1241, 752], "text": "therapy."}]}, {"boundingBox": [335, 778, 1254, 776, 1255, 813, 336, 814], "text": "There is broad and substantial recognition of the relationship of", "words": [{"boundingBox": [338, 778, 416, 779, 416, 814, 338, 814], "text": "There"}, {"boundingBox": [423, 779, 449, 780, 449, 814, 423, 814], "text": "is"}, {"boundingBox": [456, 780, 543, 780, 543, 814, 456, 814], "text": "broad"}, {"boundingBox": [550, 780, 604, 781, 604, 814, 550, 814], "text": "and"}, {"boundingBox": [611, 781, 769, 781, 769, 814, 612, 814], "text": "substantial"}, {"boundingBox": [776, 781, 945, 781, 946, 814, 777, 814], "text": "recognition"}, {"boundingBox": [952, 781, 983, 781, 984, 814, 953, 814], "text": "of"}, {"boundingBox": [990, 781, 1035, 780, 1036, 813, 991, 814], "text": "the"}, {"boundingBox": [1042, 780, 1216, 778, 1217, 813, 1043, 813], "text": "relationship"}, {"boundingBox": [1223, 778, 1253, 778, 1255, 813, 1224, 813], "text": "of"}]}, {"boundingBox": [334, 821, 1048, 822, 1047, 854, 333, 853], "text": "diabetic dyslipidemia and cardiovascular disease.", "words": [{"boundingBox": [340, 821, 452, 823, 453, 853, 341, 852], "text": "diabetic"}, {"boundingBox": [458, 823, 639, 825, 640, 854, 459, 853], "text": "dyslipidemia"}, {"boundingBox": [645, 825, 700, 825, 702, 854, 646, 854], "text": "and"}, {"boundingBox": [708, 825, 923, 825, 924, 853, 709, 854], "text": "cardiovascular"}, {"boundingBox": [929, 825, 1045, 824, 1047, 852, 930, 853], "text": "disease."}]}, {"boundingBox": [335, 874, 1295, 873, 1296, 907, 335, 908], "text": "TZDs are currently perceived to be better than other OADs on most", "words": [{"boundingBox": [337, 874, 411, 875, 412, 907, 338, 906], "text": "TZDs"}, {"boundingBox": [418, 875, 464, 876, 466, 907, 419, 907], "text": "are"}, {"boundingBox": [471, 876, 596, 877, 598, 908, 472, 907], "text": "currently"}, {"boundingBox": [603, 877, 748, 878, 749, 909, 604, 908], "text": "perceived"}, {"boundingBox": [754, 878, 784, 878, 785, 909, 755, 909], "text": "to"}, {"boundingBox": [790, 878, 826, 878, 828, 909, 792, 909], "text": "be"}, {"boundingBox": [833, 878, 920, 878, 922, 908, 834, 909], "text": "better"}, {"boundingBox": [927, 878, 993, 877, 994, 908, 928, 908], "text": "than"}, {"boundingBox": [999, 877, 1078, 877, 1079, 908, 1001, 908], "text": "other"}, {"boundingBox": [1084, 877, 1169, 876, 1171, 907, 1086, 908], "text": "OADs"}, {"boundingBox": [1176, 876, 1212, 876, 1214, 907, 1177, 907], "text": "on"}, {"boundingBox": [1218, 876, 1293, 875, 1295, 906, 1220, 906], "text": "most"}]}, {"boundingBox": [333, 915, 1300, 914, 1301, 948, 334, 949], "text": "concepts related to IR and vascular health. Most believe that TZDs", "words": [{"boundingBox": [336, 916, 467, 915, 467, 950, 336, 949], "text": "concepts"}, {"boundingBox": [474, 915, 574, 915, 574, 950, 474, 950], "text": "related"}, {"boundingBox": [581, 915, 609, 915, 609, 950, 581, 950], "text": "to"}, {"boundingBox": [616, 915, 648, 915, 648, 950, 616, 950], "text": "IR"}, {"boundingBox": [657, 915, 712, 915, 712, 950, 657, 950], "text": "and"}, {"boundingBox": [718, 915, 841, 915, 840, 950, 718, 950], "text": "vascular"}, {"boundingBox": [847, 915, 956, 915, 956, 950, 847, 950], "text": "health."}, {"boundingBox": [963, 915, 1035, 915, 1035, 949, 963, 950], "text": "Most"}, {"boundingBox": [1041, 915, 1148, 915, 1148, 949, 1041, 949], "text": "believe"}, {"boundingBox": [1155, 915, 1214, 915, 1214, 949, 1155, 949], "text": "that"}, {"boundingBox": [1221, 915, 1299, 915, 1299, 948, 1220, 949], "text": "TZDs"}]}, {"boundingBox": [340, 954, 1187, 955, 1186, 989, 339, 988], "text": "have the best potential for a positive cardiovascular profile.", "words": [{"boundingBox": [340, 954, 404, 955, 404, 988, 340, 988], "text": "have"}, {"boundingBox": [411, 955, 458, 956, 458, 989, 411, 988], "text": "the"}, {"boundingBox": [464, 956, 527, 957, 527, 989, 464, 989], "text": "best"}, {"boundingBox": [533, 957, 660, 958, 660, 989, 533, 989], "text": "potential"}, {"boundingBox": [666, 958, 711, 958, 711, 989, 667, 989], "text": "for"}, {"boundingBox": [717, 958, 735, 958, 736, 989, 718, 989], "text": "a"}, {"boundingBox": [742, 958, 859, 959, 860, 989, 742, 989], "text": "positive"}, {"boundingBox": [866, 959, 1079, 958, 1080, 988, 867, 989], "text": "cardiovascular"}, {"boundingBox": [1086, 958, 1186, 957, 1187, 988, 1087, 988], "text": "profile."}]}, {"boundingBox": [333, 1015, 1240, 1016, 1239, 1050, 332, 1049], "text": "Participants accept ACTOS as an effective and liver-safe agent.", "words": [{"boundingBox": [336, 1016, 508, 1016, 508, 1050, 335, 1049], "text": "Participants"}, {"boundingBox": [515, 1016, 612, 1016, 612, 1051, 515, 1050], "text": "accept"}, {"boundingBox": [619, 1016, 723, 1016, 723, 1051, 619, 1051], "text": "ACTOS"}, {"boundingBox": [729, 1016, 765, 1016, 765, 1051, 730, 1051], "text": "as"}, {"boundingBox": [771, 1016, 807, 1016, 807, 1051, 772, 1051], "text": "an"}, {"boundingBox": [813, 1017, 940, 1017, 940, 1051, 814, 1051], "text": "effective"}, {"boundingBox": [946, 1017, 1001, 1017, 1002, 1051, 947, 1051], "text": "and"}, {"boundingBox": [1008, 1017, 1143, 1017, 1144, 1050, 1009, 1051], "text": "liver-safe"}, {"boundingBox": [1150, 1017, 1238, 1018, 1240, 1050, 1151, 1050], "text": "agent."}]}, {"boundingBox": [336, 1064, 1340, 1067, 1339, 1103, 335, 1101], "text": "ACTOS is currently perceived to be better than or equal to Avandia on", "words": [{"boundingBox": [337, 1065, 438, 1067, 437, 1102, 336, 1102], "text": "ACTOS"}, {"boundingBox": [445, 1067, 474, 1067, 473, 1102, 445, 1102], "text": "is"}, {"boundingBox": [481, 1067, 606, 1069, 606, 1102, 481, 1102], "text": "currently"}, {"boundingBox": [613, 1069, 755, 1070, 755, 1102, 613, 1102], "text": "perceived"}, {"boundingBox": [762, 1070, 793, 1070, 794, 1102, 763, 1102], "text": "to"}, {"boundingBox": [801, 1070, 837, 1070, 837, 1102, 801, 1102], "text": "be"}, {"boundingBox": [844, 1070, 928, 1070, 929, 1103, 844, 1102], "text": "better"}, {"boundingBox": [935, 1070, 1003, 1070, 1003, 1103, 936, 1103], "text": "than"}, {"boundingBox": [1010, 1070, 1043, 1070, 1044, 1103, 1011, 1103], "text": "or"}, {"boundingBox": [1051, 1070, 1130, 1070, 1131, 1103, 1052, 1103], "text": "equal"}, {"boundingBox": [1137, 1070, 1168, 1069, 1170, 1103, 1138, 1103], "text": "to"}, {"boundingBox": [1176, 1069, 1291, 1068, 1293, 1103, 1177, 1103], "text": "Avandia"}, {"boundingBox": [1298, 1068, 1339, 1067, 1341, 1103, 1300, 1103], "text": "on"}]}, {"boundingBox": [332, 1105, 898, 1104, 899, 1138, 333, 1139], "text": "all key attributes, including lipid effects.", "words": [{"boundingBox": [335, 1105, 370, 1105, 371, 1138, 335, 1138], "text": "all"}, {"boundingBox": [377, 1105, 427, 1105, 428, 1139, 377, 1139], "text": "key"}, {"boundingBox": [434, 1105, 579, 1105, 579, 1139, 434, 1139], "text": "attributes,"}, {"boundingBox": [585, 1105, 723, 1105, 724, 1139, 586, 1139], "text": "including"}, {"boundingBox": [730, 1105, 796, 1105, 796, 1139, 730, 1139], "text": "lipid"}, {"boundingBox": [802, 1105, 899, 1105, 899, 1138, 803, 1139], "text": "effects."}]}, {"boundingBox": [334, 1153, 1291, 1154, 1291, 1191, 333, 1190], "text": "While participants accept the head-to-head lipid studies as validly-", "words": [{"boundingBox": [336, 1155, 417, 1156, 417, 1188, 336, 1188], "text": "While"}, {"boundingBox": [424, 1156, 595, 1157, 595, 1188, 423, 1188], "text": "participants"}, {"boundingBox": [601, 1157, 698, 1158, 698, 1189, 601, 1188], "text": "accept"}, {"boundingBox": [704, 1158, 750, 1158, 750, 1189, 704, 1189], "text": "the"}, {"boundingBox": [757, 1158, 947, 1157, 948, 1189, 757, 1189], "text": "head-to-head"}, {"boundingBox": [954, 1157, 1022, 1157, 1023, 1190, 954, 1189], "text": "lipid"}, {"boundingBox": [1028, 1157, 1136, 1156, 1137, 1190, 1029, 1190], "text": "studies"}, {"boundingBox": [1142, 1156, 1177, 1155, 1178, 1190, 1143, 1190], "text": "as"}, {"boundingBox": [1184, 1155, 1289, 1154, 1290, 1191, 1185, 1191], "text": "validly-"}]}, {"boundingBox": [338, 1191, 1303, 1193, 1302, 1226, 337, 1225], "text": "conducted research (with some reservations), most are reluctant to", "words": [{"boundingBox": [338, 1192, 485, 1193, 485, 1225, 339, 1225], "text": "conducted"}, {"boundingBox": [492, 1193, 618, 1194, 618, 1225, 492, 1225], "text": "research"}, {"boundingBox": [625, 1194, 700, 1194, 700, 1225, 625, 1225], "text": "(with"}, {"boundingBox": [707, 1194, 784, 1194, 785, 1225, 707, 1225], "text": "some"}, {"boundingBox": [791, 1194, 991, 1194, 991, 1226, 791, 1225], "text": "reservations),"}, {"boundingBox": [997, 1194, 1075, 1194, 1075, 1226, 997, 1226], "text": "most"}, {"boundingBox": [1082, 1194, 1128, 1194, 1128, 1226, 1082, 1226], "text": "are"}, {"boundingBox": [1135, 1194, 1264, 1193, 1263, 1227, 1135, 1226], "text": "reluctant"}, {"boundingBox": [1270, 1193, 1301, 1193, 1301, 1227, 1270, 1227], "text": "to"}]}, {"boundingBox": [335, 1228, 996, 1229, 995, 1263, 334, 1262], "text": "attach a great deal of clinical value to the data.", "words": [{"boundingBox": [335, 1230, 424, 1230, 424, 1263, 335, 1263], "text": "attach"}, {"boundingBox": [430, 1230, 450, 1230, 450, 1263, 431, 1263], "text": "a"}, {"boundingBox": [456, 1230, 537, 1229, 537, 1262, 457, 1263], "text": "great"}, {"boundingBox": [543, 1229, 599, 1229, 600, 1262, 543, 1262], "text": "deal"}, {"boundingBox": [606, 1229, 636, 1229, 636, 1262, 606, 1262], "text": "of"}, {"boundingBox": [643, 1229, 747, 1230, 747, 1262, 643, 1262], "text": "clinical"}, {"boundingBox": [753, 1230, 833, 1230, 834, 1263, 753, 1262], "text": "value"}, {"boundingBox": [840, 1230, 870, 1231, 870, 1263, 840, 1263], "text": "to"}, {"boundingBox": [877, 1231, 927, 1231, 927, 1263, 877, 1263], "text": "the"}, {"boundingBox": [935, 1231, 996, 1232, 996, 1263, 935, 1263], "text": "data."}]}, {"boundingBox": [333, 1280, 1300, 1280, 1299, 1314, 332, 1313], "text": "Head-to-head data from clinical studies (TZDs vs. other OADs, AND", "words": [{"boundingBox": [335, 1280, 530, 1281, 531, 1314, 335, 1313], "text": "Head-to-head"}, {"boundingBox": [536, 1281, 596, 1281, 597, 1314, 537, 1314], "text": "data"}, {"boundingBox": [603, 1281, 663, 1281, 664, 1315, 604, 1315], "text": "from"}, {"boundingBox": [678, 1281, 783, 1281, 784, 1315, 679, 1315], "text": "clinical"}, {"boundingBox": [789, 1281, 897, 1281, 898, 1315, 791, 1315], "text": "studies"}, {"boundingBox": [903, 1281, 991, 1281, 993, 1315, 905, 1315], "text": "(TZDs"}, {"boundingBox": [998, 1281, 1043, 1281, 1044, 1315, 999, 1315], "text": "vs."}, {"boundingBox": [1049, 1281, 1126, 1281, 1128, 1315, 1051, 1315], "text": "other"}, {"boundingBox": [1133, 1281, 1227, 1281, 1229, 1314, 1134, 1315], "text": "OADs,"}, {"boundingBox": [1233, 1281, 1296, 1281, 1298, 1314, 1235, 1314], "text": "AND"}]}, {"boundingBox": [334, 1315, 1339, 1318, 1338, 1352, 333, 1349], "text": "ACTOS vs. Avandia) is needed to significantly alter prescribing habits.", "words": [{"boundingBox": [336, 1316, 439, 1317, 440, 1350, 338, 1350], "text": "ACTOS"}, {"boundingBox": [445, 1317, 490, 1318, 492, 1350, 447, 1350], "text": "vs."}, {"boundingBox": [497, 1318, 621, 1318, 623, 1351, 498, 1350], "text": "Avandia)"}, {"boundingBox": [628, 1319, 655, 1319, 656, 1351, 630, 1351], "text": "is"}, {"boundingBox": [661, 1319, 768, 1319, 770, 1351, 663, 1351], "text": "needed"}, {"boundingBox": [775, 1319, 806, 1319, 808, 1351, 777, 1351], "text": "to"}, {"boundingBox": [813, 1319, 991, 1319, 993, 1352, 814, 1351], "text": "significantly"}, {"boundingBox": [998, 1319, 1062, 1319, 1064, 1352, 999, 1352], "text": "alter"}, {"boundingBox": [1069, 1319, 1236, 1319, 1237, 1352, 1070, 1352], "text": "prescribing"}, {"boundingBox": [1242, 1319, 1338, 1318, 1340, 1353, 1244, 1352], "text": "habits."}]}, {"boundingBox": [331, 1375, 1242, 1378, 1241, 1413, 330, 1409], "text": "Splitters and High Potentials responded similarly with regard to", "words": [{"boundingBox": [336, 1375, 457, 1376, 458, 1410, 337, 1410], "text": "Splitters"}, {"boundingBox": [464, 1376, 517, 1377, 518, 1411, 465, 1410], "text": "and"}, {"boundingBox": [524, 1377, 593, 1378, 593, 1411, 525, 1411], "text": "High"}, {"boundingBox": [599, 1378, 744, 1379, 745, 1411, 600, 1411], "text": "Potentials"}, {"boundingBox": [751, 1379, 909, 1380, 910, 1412, 752, 1411], "text": "responded"}, {"boundingBox": [916, 1380, 1040, 1380, 1040, 1412, 917, 1412], "text": "similarly"}, {"boundingBox": [1047, 1380, 1109, 1381, 1109, 1411, 1047, 1412], "text": "with"}, {"boundingBox": [1116, 1381, 1212, 1381, 1212, 1411, 1116, 1411], "text": "regard"}, {"boundingBox": [1219, 1381, 1242, 1381, 1242, 1411, 1219, 1411], "text": "to"}]}, {"boundingBox": [335, 1412, 1251, 1415, 1250, 1447, 334, 1444], "text": "most of the observed core issues, although Splitters are clearly", "words": [{"boundingBox": [335, 1412, 410, 1413, 410, 1445, 335, 1444], "text": "most"}, {"boundingBox": [416, 1413, 445, 1413, 445, 1445, 416, 1445], "text": "of"}, {"boundingBox": [451, 1413, 499, 1413, 499, 1445, 452, 1445], "text": "the"}, {"boundingBox": [505, 1413, 640, 1414, 641, 1446, 506, 1445], "text": "observed"}, {"boundingBox": [646, 1414, 710, 1414, 711, 1446, 647, 1446], "text": "core"}, {"boundingBox": [717, 1414, 822, 1415, 823, 1446, 717, 1446], "text": "issues,"}, {"boundingBox": [829, 1415, 959, 1415, 960, 1447, 829, 1446], "text": "although"}, {"boundingBox": [968, 1415, 1090, 1416, 1091, 1447, 969, 1447], "text": "Splitters"}, {"boundingBox": [1096, 1416, 1144, 1416, 1145, 1447, 1097, 1447], "text": "are"}, {"boundingBox": [1150, 1416, 1250, 1416, 1251, 1446, 1151, 1447], "text": "clearly"}]}, {"boundingBox": [336, 1446, 1267, 1450, 1267, 1483, 335, 1479], "text": "more likely than High Potentials to use TZDs as first-line therapy.", "words": [{"boundingBox": [336, 1448, 410, 1448, 410, 1480, 336, 1479], "text": "more"}, {"boundingBox": [416, 1448, 492, 1448, 493, 1480, 417, 1480], "text": "likely"}, {"boundingBox": [499, 1448, 563, 1448, 563, 1480, 499, 1480], "text": "than"}, {"boundingBox": [569, 1448, 639, 1448, 639, 1481, 569, 1480], "text": "High"}, {"boundingBox": [645, 1448, 792, 1449, 792, 1481, 646, 1481], "text": "Potentials"}, {"boundingBox": [798, 1449, 829, 1449, 829, 1481, 798, 1481], "text": "to"}, {"boundingBox": [835, 1449, 891, 1449, 891, 1482, 836, 1482], "text": "use"}, {"boundingBox": [899, 1449, 973, 1449, 974, 1482, 900, 1482], "text": "TZDs"}, {"boundingBox": [979, 1449, 1017, 1450, 1017, 1482, 980, 1482], "text": "as"}, {"boundingBox": [1023, 1450, 1142, 1450, 1143, 1483, 1023, 1482], "text": "first-line"}, {"boundingBox": [1149, 1450, 1266, 1451, 1267, 1484, 1149, 1483], "text": "therapy."}]}, {"boundingBox": [325, 1505, 1308, 1506, 1307, 1538, 325, 1538], "text": "All groups believe that ACTOS can be shown to be valid foundation", "words": [{"boundingBox": [338, 1506, 376, 1506, 372, 1538, 333, 1538], "text": "All"}, {"boundingBox": [383, 1506, 484, 1506, 480, 1538, 379, 1538], "text": "groups"}, {"boundingBox": [491, 1506, 595, 1507, 591, 1539, 487, 1538], "text": "believe"}, {"boundingBox": [601, 1507, 659, 1507, 656, 1539, 597, 1539], "text": "that"}, {"boundingBox": [666, 1507, 769, 1507, 766, 1539, 662, 1539], "text": "ACTOS"}, {"boundingBox": [776, 1507, 830, 1507, 827, 1539, 773, 1539], "text": "can"}, {"boundingBox": [836, 1507, 875, 1507, 872, 1539, 833, 1539], "text": "be"}, {"boundingBox": [882, 1507, 979, 1507, 976, 1539, 879, 1539], "text": "shown"}, {"boundingBox": [985, 1507, 1016, 1507, 1013, 1539, 983, 1539], "text": "to"}, {"boundingBox": [1022, 1507, 1061, 1507, 1059, 1539, 1020, 1539], "text": "be"}, {"boundingBox": [1067, 1508, 1136, 1508, 1134, 1539, 1065, 1539], "text": "valid"}, {"boundingBox": [1143, 1508, 1303, 1508, 1301, 1539, 1141, 1539], "text": "foundation"}]}, {"boundingBox": [336, 1542, 1231, 1545, 1230, 1576, 335, 1573], "text": "therapy, assuming the accumulation of clinical outcomes data.", "words": [{"boundingBox": [336, 1543, 451, 1544, 451, 1573, 336, 1572], "text": "therapy,"}, {"boundingBox": [457, 1544, 598, 1544, 598, 1574, 457, 1573], "text": "assuming"}, {"boundingBox": [605, 1544, 654, 1544, 653, 1575, 605, 1574], "text": "the"}, {"boundingBox": [661, 1544, 854, 1545, 854, 1575, 661, 1575], "text": "accumulation"}, {"boundingBox": [863, 1545, 895, 1545, 895, 1575, 863, 1575], "text": "of"}, {"boundingBox": [900, 1545, 1008, 1545, 1008, 1575, 900, 1575], "text": "clinical"}, {"boundingBox": [1014, 1545, 1158, 1545, 1158, 1575, 1014, 1575], "text": "outcomes"}, {"boundingBox": [1166, 1546, 1231, 1546, 1231, 1575, 1166, 1575], "text": "data.", "confidence": "Low"}]}, {"boundingBox": [329, 1596, 1312, 1601, 1311, 1636, 328, 1632], "text": "Metformin is an effective and trusted agent. Doctors caution against", "words": [{"boundingBox": [335, 1597, 482, 1598, 480, 1632, 333, 1630], "text": "Metformin"}, {"boundingBox": [489, 1598, 517, 1598, 516, 1632, 487, 1632], "text": "is"}, {"boundingBox": [524, 1598, 559, 1598, 557, 1633, 522, 1633], "text": "an"}, {"boundingBox": [565, 1598, 690, 1599, 689, 1634, 564, 1633], "text": "effective"}, {"boundingBox": [697, 1599, 752, 1599, 751, 1634, 696, 1634], "text": "and"}, {"boundingBox": [758, 1599, 861, 1600, 861, 1635, 757, 1634], "text": "trusted"}, {"boundingBox": [868, 1600, 960, 1600, 960, 1635, 867, 1635], "text": "agent."}, {"boundingBox": [967, 1600, 1083, 1601, 1083, 1635, 966, 1635], "text": "Doctors"}, {"boundingBox": [1090, 1601, 1199, 1601, 1199, 1635, 1090, 1635], "text": "caution"}, {"boundingBox": [1206, 1601, 1311, 1601, 1312, 1635, 1206, 1635], "text": "against"}]}, {"boundingBox": [333, 1632, 1267, 1639, 1266, 1673, 332, 1667], "text": "fighting against it - instead, promote combo use with metformin.", "words": [{"boundingBox": [336, 1633, 445, 1634, 444, 1669, 335, 1668], "text": "fighting"}, {"boundingBox": [452, 1634, 559, 1635, 558, 1670, 451, 1669], "text": "against"}, {"boundingBox": [566, 1635, 584, 1635, 583, 1670, 565, 1670], "text": "it"}, {"boundingBox": [591, 1636, 609, 1636, 608, 1670, 590, 1670], "text": "-"}, {"boundingBox": [616, 1636, 734, 1637, 733, 1671, 615, 1670], "text": "instead,"}, {"boundingBox": [741, 1637, 864, 1638, 863, 1671, 740, 1671], "text": "promote"}, {"boundingBox": [870, 1638, 971, 1638, 970, 1672, 870, 1671], "text": "combo"}, {"boundingBox": [977, 1638, 1032, 1639, 1032, 1672, 977, 1672], "text": "use"}, {"boundingBox": [1039, 1639, 1100, 1639, 1100, 1672, 1038, 1672], "text": "with"}, {"boundingBox": [1107, 1639, 1266, 1640, 1266, 1672, 1107, 1672], "text": "metformin."}]}, {"boundingBox": [333, 1692, 1339, 1697, 1339, 1733, 332, 1728], "text": "The most commonly mentioned reasons NOT to prescribe TZDs are 1)", "words": [{"boundingBox": [337, 1696, 389, 1696, 390, 1727, 338, 1727], "text": "The"}, {"boundingBox": [395, 1696, 470, 1697, 471, 1728, 396, 1727], "text": "most"}, {"boundingBox": [476, 1697, 625, 1697, 626, 1729, 477, 1728], "text": "commonly"}, {"boundingBox": [632, 1697, 787, 1698, 788, 1730, 632, 1729], "text": "mentioned"}, {"boundingBox": [793, 1698, 912, 1698, 913, 1731, 794, 1730], "text": "reasons"}, {"boundingBox": [918, 1698, 985, 1698, 985, 1731, 919, 1731], "text": "NOT"}, {"boundingBox": [991, 1698, 1021, 1698, 1022, 1732, 991, 1731], "text": "to"}, {"boundingBox": [1027, 1698, 1167, 1698, 1167, 1733, 1028, 1732], "text": "prescribe"}, {"boundingBox": [1175, 1698, 1249, 1697, 1250, 1733, 1175, 1733], "text": "TZDs"}, {"boundingBox": [1255, 1697, 1304, 1697, 1304, 1733, 1256, 1733], "text": "are"}, {"boundingBox": [1310, 1697, 1338, 1697, 1338, 1734, 1310, 1733], "text": "1)"}]}, {"boundingBox": [333, 1727, 1074, 1732, 1073, 1769, 332, 1764], "text": "Cost, 2) Edema/weight gain, and 3) Reimbursement.", "words": [{"boundingBox": [335, 1730, 411, 1730, 412, 1764, 336, 1762], "text": "Cost,"}, {"boundingBox": [417, 1730, 445, 1729, 446, 1764, 419, 1764], "text": "2)"}, {"boundingBox": [451, 1729, 657, 1730, 658, 1767, 453, 1764], "text": "Edema/weight"}, {"boundingBox": [663, 1730, 736, 1731, 736, 1768, 664, 1767], "text": "gain,"}, {"boundingBox": [742, 1731, 797, 1731, 798, 1768, 743, 1768], "text": "and"}, {"boundingBox": [803, 1731, 833, 1732, 834, 1768, 804, 1768], "text": "3)"}, {"boundingBox": [840, 1732, 1073, 1735, 1073, 1767, 840, 1768], "text": "Reimbursement."}]}, {"boundingBox": [768, 1836, 798, 1832, 799, 1865, 769, 1868], "text": "2", "words": [{"boundingBox": [773, 1834, 795, 1831, 799, 1864, 777, 1867], "text": "2"}]}, {"boundingBox": [61, 2068, 497, 2069, 497, 2100, 60, 2099], "text": "Confidential - Subject to Protective Order", "words": [{"boundingBox": [61, 2069, 181, 2070, 181, 2100, 62, 2100], "text": "Confidential"}, {"boundingBox": [187, 2070, 203, 2070, 203, 2099, 187, 2100], "text": "-"}, {"boundingBox": [209, 2070, 287, 2070, 287, 2099, 209, 2099], "text": "Subject"}, {"boundingBox": [294, 2070, 314, 2070, 314, 2100, 294, 2099], "text": "to"}, {"boundingBox": [320, 2070, 427, 2070, 427, 2100, 320, 2100], "text": "Protective"}, {"boundingBox": [433, 2070, 497, 2069, 497, 2101, 433, 2100], "text": "Order"}]}, {"boundingBox": [1238, 2066, 1496, 2069, 1495, 2097, 1237, 2093], "text": "TAK-DALYRI-00058798", "words": [{"boundingBox": [1243, 2067, 1497, 2071, 1497, 2096, 1244, 2094], "text": "TAK-DALYRI-00058798"}]}, {"boundingBox": [1212, 2101, 1568, 2102, 1567, 2131, 1211, 2130], "text": "Produced in MDL on 09/17/12", "words": [{"boundingBox": [1217, 2103, 1330, 2104, 1330, 2131, 1217, 2130], "text": "Produced"}, {"boundingBox": [1335, 2104, 1357, 2104, 1358, 2131, 1336, 2131], "text": "in"}, {"boundingBox": [1362, 2104, 1419, 2104, 1420, 2131, 1363, 2131], "text": "MDL"}, {"boundingBox": [1424, 2104, 1455, 2104, 1456, 2131, 1425, 2131], "text": "on"}, {"boundingBox": [1460, 2104, 1566, 2102, 1567, 2132, 1461, 2131], "text": "09/17/12"}]}, {"boundingBox": [384, 2194, 1317, 2191, 1318, 2230, 385, 2233], "text": "Source: https://www.induptygacoo093ts.ucsf.edu/docs/rnjf0226", "words": [{"boundingBox": [387, 2196, 501, 2196, 502, 2231, 387, 2231], "text": "Source:"}, {"boundingBox": [508, 2196, 1316, 2192, 1317, 2229, 508, 2232], "text": "https://www.induptygacoo093ts.ucsf.edu/docs/rnjf0226", "confidence": "Low"}]}]}]}